Vir Biotechnology Has Dosed The First Participant In A Phase 1 Trial Of VIR-1388, An Investigational Novel T Cell Vaccine For The Prevention Of Human Immunodeficiency Virus; Initial Data Expected In 2H Of 2024
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology has initiated a Phase 1 trial of VIR-1388, a novel T cell vaccine for the prevention of HIV. The first participant has been dosed and initial data from the trial is expected in the second half of 2024.
September 20, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vir Biotechnology has started a Phase 1 trial for its HIV prevention vaccine, VIR-1388. Initial results are expected in 2H 2024.
The initiation of the Phase 1 trial for VIR-1388 is a significant milestone for Vir Biotechnology. This could potentially lead to a new product offering in the future, which could boost the company's revenues and profitability. However, the results are not expected until the second half of 2024, so the immediate impact on the stock price may be limited.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100